Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

DAC plus ATRA regimen may be effective for elderly AML patients

Publish date:: May 20, 2020

Key clinical point: Decitabine plus all-trans retinoic acid showed benefits in elderly acute myeloid leukemia patients and cultured cells.

Major finding: 44.4 % of patients achieved CR; 11.1 % achieved CR with incomplete peripheral count recovery; and 13.9 % achieved partial remission.

Study details: Clinical trial of 36 elderly AML patients who were judged ineligible for conventional chemotherapy.

Disclosures: The study was sponsored by Jiangsu Province, China. The authors reported that they had no conflicts.

Citation:

Cao Y et al. Biomedicine & Pharmacotherapy. 2020;125: doi.org/10.1016/j.biopha.2020.109878.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in AML

Beat AML: Precision medicine strategy feasible, superior to SOC for AML,

Survey quantifies COVID-19’s impact on oncology,

Combo drug improves survival in older patients with high-risk/secondary AML,

Venetoclax plus LDAC tops LDAC alone in AML,

Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML,